Artiva Biotherapeutics, Inc. logo ARTV - Artiva Biotherapeutics, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY
0
BUY 4
HOLD 0
SELL 0
STRONG
SELL
0
| PRICE TARGET: $37.50 DETAILS
HIGH: $40.00
LOW: $35.00
MEDIAN: $37.50
CONSENSUS: $37.50
UPSIDE: 400.67%
Metric 2026 Q2 2026 Q1 2025 Q4 2025 Q3 2025 Q2 2025 Q1 2024 Q4 2024 Q3 2024 Q2 2024 Q1 2023 Q4 2023 Q3 2023 Q2 2023 Q1
Revenue
Revenue 0 0 0 0 0 0 0 0 0 0.3 2.4 26.7 3.5 1.0
Cost of Revenue 0 0.7 0 0 0 0 0 0 0 0 0 0 0 0
Gross Profit 0 (0.7) 0 0 0 0 0 0 0 0.3 2.4 26.7 3.5 1.0
Operating Expenses
R&D Expenses 21.9 19.3 17.0 17.6 17.9 17.1 13.3 13.5 12.3 11.2 11.2 13.1 11.3 14.8
SG&A Expenses 5.0 5.1 4.9 5.3 4.9 5.1 5.0 4.8 3.9 3.6 3.2 2.8 4.1 3.9
Other Expenses 0 (0.7) 0 0 0 0 0 0 0 0 0 0 0 0
Operating Expenses 26.9 23.8 21.9 22.9 22.8 22.2 18.3 18.3 16.2 14.7 14.3 15.8 15.3 18.7
Operating Income
Operating Income (26.9) (24.4) (21.9) (22.9) (22.8) (22.2) (18.3) (18.3) (16.2) (14.5) (12.0) 10.8 (11.8) (17.7)
Interest Expense 0 0 0 0 0 0 0 0 0 0 0 0 0.5 0
Interest Income 1.9 0.9 1.2 1.4 1.6 1.9 2.2 1.8 0.7 0.7 0.6 0.4 0 1.0
Profitability
EBITDA (23.6) (22.9) (20.1) (20.9) (20.6) (19.7) (8.6) (16.8) (17.2) (13.4) (11.3) 11.8 (10.2) (16.1)
EBIT (25.0) (23.5) (20.8) (21.5) (21.3) (20.3) (9.2) (17.5) (17.8) (14.0) (11.9) 11.3 (10.8) (16.7)
Income Before Tax (25.0) (23.5) (20.8) (21.5) (21.3) (20.3) (9.2) (17.5) (17.8) (14.0) (11.9) 11.3 (11.3) (16.7)
Income Tax Expense 0 0 0 0 0 0 0 0 0 0 0.1 0 0 0
Net Income (25.0) (23.5) (20.8) (21.5) (21.3) (20.3) (9.2) (17.5) (17.8) (14.0) (12.0) 11.3 (11.3) (16.7)
Per Share Data
EPS (Basic) -0.63 -0.95 -0.85 -0.88 -0.87 -0.83 -0.82 -0.92 -0.62 -0.79 -0.54 0.59 -0.90 -0.95
EPS (Diluted) -0.63 -0.95 -0.85 -0.88 -0.87 -0.83 -0.82 -0.92 -0.62 -0.79 -0.54 0.59 -0.90 -0.95
Shares Outstanding 39.4 24.7 24.4 24.5 24.4 24.3 24.4 24.3 23.3 17.6 20.4 19.0 17.6 17.6
Metric 2026 Q2 2026 Q1 2025 Q4 2025 Q3 2025 Q2 2025 Q1 2024 Q4 2024 Q3 2024 Q2 2024 Q1 2023 Q4
Current Assets
Cash & Cash Equivalents 301.5 21.0 26.7 25.5 28.5 30.4 40.2 55.9 34.2 48.2 53.5
Short-Term Investments 47.9 65.8 81.3 97.5 113.9 135.6 145.2 90.8 12.3 13.9 23.5
Net Receivables 0.1 0.6 0.8 0.9 0.0 1.0 0.1 0.7 1.5 1.7 1.8
Inventory 0 0 0 0 0 0 0 0 0 0 0
Other Current Assets 0 1.4 3.9 5.7 6.7 3.0 3.1 3.2 1.7 2.0 1.1
Total Current Assets 352.3 88.7 112.7 129.5 149.1 170.0 188.6 150.6 49.7 65.9 79.8
Non-Current Assets
Property, Plant & Equipment 15.1 16.3 17.4 18.5 19.8 20.8 20.4 21.5 22.7 23.4 24.6
Goodwill 0 0 0 0 0 0 0 0 0 0 0
Intangible Assets 0 0 0 0 0 0 0 0 0 0 0
Long-Term Investments 0 0 0 0.5 0 0 0 53.0 0 0 0
Other Non-Current Assets 1.3 0.9 0.9 0.4 0.5 0.5 0.5 0.6 3.4 0.9 0.7
Total Non-Current Assets 16.4 17.2 18.3 19.3 20.3 21.3 20.9 75.0 26.2 24.3 25.3
Total Assets 368.6 106.0 130.9 148.9 169.4 191.3 209.6 225.6 75.9 90.2 105.1
Current Liabilities
Account Payables 0 2.3 0.4 0.8 1.2 2.0 1.1 1.2 0.8 1.5 0.6
Short-Term Debt 0 3.0 3.1 3.2 0 0 0 0 0 0 0
Deferred Revenue 0 0 0 0 0 0 0 0 0 0 0
Other Current Liabilities 1.4 2.4 2.1 1.5 0.1 0.1 0 0 0 0 0
Total Current Liabilities 14.6 10.9 13.1 11.1 10.8 12.2 12.3 13.3 10.8 10.4 12.2
Non-Current Liabilities
Long-Term Debt 0 7.2 7.9 0 0 0 0 0 0 0 0
Deferred Tax Liabilities 0 0 0 0 0 0 0 0 0 0 0
Other Non-Current Liabilities 0 0 0 0 0 0 0.1 0.1 244.2 241.9 241.6
Total Non-Current Liabilities 6.5 7.2 7.9 8.5 9.6 10.3 10.7 11.3 256.2 254.5 254.9
Total Liabilities 21.1 18.1 21.0 19.6 20.4 22.5 22.9 24.6 267.0 264.8 267.1
Stockholders' Equity
Common Stock 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0 0 0
Retained Earnings (379.1) (354.1) (330.5) (309.8) (288.2) (267.0) (246.7) (230.6) (213.1) (195.3) (181.3)
Accumulated Other Comprehensive Income (0.0) (0.0) 0.1 0.1 0.0 0 (0.1) 0.3 0.1 0.2 0.3
Total Stockholders' Equity 347.5 87.8 110.0 129.2 149.0 168.8 186.6 201.0 (191.1) (174.7) (162.0)
Total Liabilities & Equity 368.6 106.0 130.9 148.9 169.4 191.3 209.6 225.6 75.9 90.2 105.1
Debt Metrics
Total Debt 9.8 10.3 10.9 11.7 13.2 14.0 14.4 15.0 15.8 16.3 16.9
Net Debt (291.6) (10.7) (15.8) (13.8) (15.2) (16.4) (25.9) (40.9) (18.5) (31.9) (36.6)
Metric 2026 Q2 2026 Q1 2025 Q4 2025 Q3 2025 Q2 2025 Q1 2024 Q4 2024 Q3 2024 Q2 2024 Q1 2023 Q4 2023 Q3 2023 Q2 2023 Q1
Operating Activities
Net Income (48.5) (23.5) (20.8) (21.5) (21.3) (20.3) (16.1) (17.5) (17.8) (14.0) (12.0) 11.3 (11.3) (16.7)
Depreciation & Amortization 1.4 0.7 1.1 0.3 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.5 0.6
Stock-Based Compensation 3.5 1.6 1.6 1.6 1.5 2.1 2.2 1.9 1.5 1.4 1.4 1.4 2.5 1.8
Change in Working Capital 2.2 0.5 (6.4) 4.9 (3.4) (1.5) (0.3) 3.0 (0.0) (3.0) (1.1) (23.8) (3.5) 0.1
Other Non-Cash Items 0.2 (0.2) 9.7 (4.5) (0.5) (0.7) (1.0) 0.3 2.1 (0.1) 0.4 (0.2) (0.0) 0
Operating Cash Flow (41.3) (20.9) (14.7) (19.2) (23.0) (19.8) (14.7) (11.6) (13.7) (15.1) (10.7) (10.7) (11.8) (14.2)
Investing Activities
Capital Expenditure (0.7) (0.2) (0.4) (0.6) (1.1) (0.5) (0.1) (0.1) (0.5) (0.0) (0.6) (0.2) (0.6) (1.9)
Acquisitions 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Purchases of Investments (6.4) (6.4) (7.5) (12.7) (6.1) (18.5) (14.9) (142.9) (12.2) (6.2) (14.8) (12.3) (22.4) 0
Sales/Maturities of Investments 40 22 24 29.6 28.2 29 13.9 12.4 14 16 12.8 12 2 0
Other Investing Activities 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Investing Cash Flow 32.9 15.3 16.0 16.3 21.1 10.0 (1.0) (130.6) 1.3 9.8 (2.7) (0.5) (21.0) (1.9)
Financing Activities
Net Debt Issuance (0.0) (0.0) 0 0 (0.0) (0.0) (0.0) (0.0) (0.1) 0 0 0 0 0
Stock Repurchased 0 0 0 0 0 0 (4.2) 166.5 0 0 0 0 0 (0.0)
Dividends Paid 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Other Financing Activities 283.1 (0.2) (0.1) (0.0) (0.0) 0.3 4.2 (2.6) (1.5) 0 1.0 23.4 0.0 0
Financing Cash Flow 283.2 (0.1) (0.1) (0.0) (0.1) 0.2 (0.0) 163.9 (1.6) 0 1.0 23.4 0.0 (0.0)
Cash Position
Net Change in Cash 274.8 (5.7) 1.2 (3.0) (1.9) (9.6) (15.6) 21.6 (14.0) (5.3) (12.4) 12.2 (32.7) (16.1)
Cash at Beginning 27.2 26.7 26.0 28.9 30.9 40.5 56.1 34.5 48.5 53.8 66.1 54.0 86.7 102.8
Cash at End 301.9 21.0 27.2 26.0 28.9 30.9 40.5 56.1 34.5 48.5 53.8 66.1 54.0 86.7
Free Cash Flow (42.0) (21.2) (15.1) (19.8) (24.0) (20.4) (14.7) (11.7) (14.1) (15.1) (11.3) (10.9) (12.3) (16.1)
Key Metrics 2026 Q2 2026 Q1 2025 Q4 2025 Q3 2025 Q2 2025 Q1 2024 Q4 2024 Q3 2024 Q2 2024 Q1 2023 Q4 2023 Q3 2023 Q2 2023 Q1
Income Statement
Revenue 0 0 0 0 0 0 0 0 0 0.3 2.4 26.7 3.5 1.0
Gross Profit 0 (0.7) 0 0 0 0 0 0 0 0.3 2.4 26.7 3.5 1.0
Operating Income (26.9) (24.4) (21.9) (22.9) (22.8) (22.2) (18.3) (18.3) (16.2) (14.5) (12.0) 10.8 (11.8) (17.7)
Net Income (25.0) (23.5) (20.8) (21.5) (21.3) (20.3) (9.2) (17.5) (17.8) (14.0) (12.0) 11.3 (11.3) (16.7)
EPS (Diluted) -0.63 -0.95 -0.85 -0.88 -0.87 -0.83 -0.82 -0.92 -0.62 -0.79 -0.54 0.59 -0.90 -0.95
Balance Sheet
Cash & Equivalents 301.5 21.0 26.7 25.5 28.5 30.4 40.2 55.9 34.2 48.2 53.5
Total Assets 368.6 106.0 130.9 148.9 169.4 191.3 209.6 225.6 75.9 90.2 105.1
Total Debt 9.8 10.3 10.9 11.7 13.2 14.0 14.4 15.0 15.8 16.3 16.9
Stockholders' Equity 347.5 87.8 110.0 129.2 149.0 168.8 186.6 201.0 (191.1) (174.7) (162.0)
Cash Flow
Operating Cash Flow (41.3) (20.9) (14.7) (19.2) (23.0) (19.8) (14.7) (11.6) (13.7) (15.1) (10.7) (10.7) (11.8) (14.2)
Capital Expenditure (0.7) (0.2) (0.4) (0.6) (1.1) (0.5) (0.1) (0.1) (0.5) (0.0) (0.6) (0.2) (0.6) (1.9)
Free Cash Flow (42.0) (21.2) (15.1) (19.8) (24.0) (20.4) (14.7) (11.7) (14.1) (15.1) (11.3) (10.9) (12.3) (16.1)